New studies demonstrate the utility of Foundation Medicine’s robust data and novel methylation sequencing to provide doctors and researchers with high-quality solutions for treatment decision making and therapy development

Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced that the company and its collaborators will present a total of 10 studies at the 2023 American Association for Cancer Research (AACR) Annual Meeting from April 14-19 in Orlando, Florida.

Presentation highlights:

• Over the past several years, there has been great progress in the ability to identify shed pieces of tumor, called circulating tumor DNA (ctDNA), within a cancer patient’s blood. In partnership with South Australian Immunogenomics Cancer Institute, Saint Bartholomew’s Hospital and Genentech, Foundation Medicine researchers used its novel methylation sequencing research platform to detect ctDNA as a prognostic biomarker in overall survival for patients with metastatic castrate resistant prostate cancer (mCRPC). Results from ctDNA evaluation as early as 6 weeks post treatment initiation were comparable to prostate specific antigen (PSA) response in second line mCRPC, providing an early non-invasive readout that is independent of PSA for monitoring therapy response in late stage mCRPC.
• Historical barriers in the study of small cell lung cancer (SCLC) include the relative lack of human tumors studied, limited real-world data, and the lack of access to longitudinal samples to understand tumor evolution. In partnership with Stanford University and Vanderbilt University Medical Center, Foundation Medicine researchers conducted what is believed to be the largest SCLC study known to date to provide an improved understanding of genetic subtypes in SCLC, including patient ancestry and biopsy site-specific patterns, and better inform mechanisms of transformation to SCLC from non-small cell lung cancer that may further guide the development of personalized therapies for subsets of patients with this fatal tumor.

“Our experience sequencing over one million patient samples has allowed us to continuously improve our approach and have high confidence in the genomic abnormalities we detect and the results we deliver,” said Priti Hegde, PhD, chief scientific officer at Foundation Medicine. “We are committed to bringing high-quality, differentiated and sustainable solutions, like options for sensitive ctDNA monitoring, to our physician and researcher partners so that they can provide all patients with the best treatment options for their unique cancers.”

The following is a list of abstracts that will be presented at the meeting. To access all abstracts being presented at AACR, please visit AACR.org.

Follow Foundation Medicine on Twitter and LinkedIn for more updates from #AACR23 and visit us in person at Booth #3053.

About Foundation Medicine: Your Essential Partner in Cancer Care

Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on www.FoundationMedicine.com and follow us on Twitter and LinkedIn.

Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

Source: Foundation Medicine

View source version on businesswire.com: https://www.businesswire.com/news/home/20230405005305/en/